Al Nakhla for Development and Training

Early Intervention Center

for Autism and Developmental Disorders



النخلة للتنمية والتطوير والتدريب

مركـز التـدخـل الـمـبـكــر للتـوحـّد واضطرابـات الـنـمــو

Director's Report on Developmental Progress Assessment

Date of Visit: 30-04-2025

Child's Name: Mohammad Mashari

Date of Birth: 17-06-2019

Assessment Summary:

The child has **improved greatly** on the first protocols. He presents with **information processing delay** and signs of **hyperlexia**, which is now progressing into **Hyperlexia Type 3**, as revealed in the **Precision Health Analysis** previously conducted.

Recommended Plan:

1. Development Protocol for Information Processing:

EICADD

- Duration: **3–4 months**
- Child should be reevaluated at the end of this period, preferably in person
- Goal: Establish a new developmental baseline and continue building cognitive flexibility and communication adaptability

2. Recommended Tests (Through Neurazon Canada):

• Neuronal Growth Factors Analysis – Neurazon (Canada)

A more detailed analysis of gut-related neuronal absorption

Sample: Hair

Timeline: 2 months business days Repeat every 6–12 months

• Functional Urine Analysis – Neurazon (Canada)

A more detailed analysis of the functional pathways and mitochondrial support

Sample: Urine

Timeline: 3 months business days Repeat every 6–12 months





Al Nakhla for Development and Training

Early Intervention Center

for Autism and Developmental Disorders



النخلة للتنمية والتطوير والتدريب

مركـز التـدخـل الـمـبـكــر للتـوحـّد واضطرابـات الـنـمــو

3. Recommended Therapy:

- Mitotherapy (Jordan): 2 sessions to support neuronal and mitochondrial repair
- Neuroplasticity Therapy (UAE):
 Ongoing sessions tailored to Hyperlexia 3 profile and sensory-cognitive integration

Conclusion:

This report is not a medical diagnosis but a developmental assessment for research and intervention planning. Mohammad shows potential for continued progress with the current trajectory. Recommendations are provided based on evidence-based findings and Neurazon protocols.

EICADD

Director

Date: 29-04-2025





